Gout is caused by the deposition of monosodium urate crystals in joints and soft tissues. It is the most common cause of inflammatory arthritis worldwide, and a cause of substantial pain and long-term disability. It is associated with several co-morbidities and often under-treated in both primary and secondary care. This article sets out the diagnosis and treatment of gout in primary care, and aims to promote self-management by patients through education of doctors.
Get full access to this article
View all access options for this article.
References
1.
AndrésMPascualEVelaP (2015) Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology54(7): 1329–1330. DOI: 10.1093/rheumatology/kev132.
2.
BMJ (2018) Latest guidance on the management of gout. BMJ362: k2893DOI: 10.1136/bmj.k2893.
3.
ChoiHKGaoXCurhanG (2009) Vitamin C intake and the risk of gout in men: A prospective study. Archives of Internal Medicine169(5): 502–507. DOI: 10.1001/archinternmed.2008.606.
4.
Drug and Therapeutics Bulletin (2016) Medicines, excipients and dietary intolerances. Drug and Therapeutics Bulletin54: 93–96. DOI: 10.1136/dtb.2016.8.0420.
HuiMCarrACameronS, et al.(2017) The British Society for Rheumatology guideline for the management of gout. Rheumatology56(7): e1–e20. DOI: 10.1093/rheumatology/kex156.
8.
Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: www.medicinescomplete.com (accessed 10 June 2019).
9.
JordanDMHyonKCVerbankM, et al.(2019) No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomisation study. PLOS Medicine16(1): e1002725DOI: 10.1371/journal.pmed.1002725.
10.
KienhorstLBJanssensHJFransenJ, et al.(2015) The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology54(4): 609–614. DOI: 10.1093/rheumatology/keu378.
11.
MallenCDDavenportGHuiM, et al.(2017) Improving management of gout in primary care: A new UK management guideline. British Journal of General Practice67(659): 284–285. DOI: 10.3399/bjgp17X691313.
12.
NICE (2008) Febuxostat for the management of hyperuricaemia in people with gout. Available at: www.nice.org.uk/guidance/ta164 (accessed 28 December 2018).
RousseauG (2009) Political gout: Dissolute patients, deceitful physicians, and other blue devils. Notes and Records of the Royal Society63(3): 277–296. DOI: 10.1098/rsnr.2009.0033.
16.
SoltaniZRasheedKKapustaDR, et al.(2013) Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: Is it time for reappraisal?Current Hypertension Reports15(3): 175–181. DOI: 10.1007/s11906-013-0344-5.e.
17.
StampLKTaylorWJJonesPB, et al.(2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis and Rheumatology64(8): 2529–2536. DOI: 10.1002/art.34488.
18.
WangWKrishnanE (2015) Cigarette smoking is associated with a reduction in the risk of incident gout: Results from the Framingham Heart Study original cohort. Rheumatology54(1): 91–95. DOI: 10.1093/rheumatology/keu304.
19.
WhiteWBSaagKGBeckerMA, et al.(2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. The New England Journal of Medicine378: 1200–1210. DOI: 10.1056/NEJMoa1710895.
